Sen Shiraj, Moreland Sarah
Department of Clinical Oncology Research, Sarah Cannon Research Institute at HealthONE, Denver, CO.
Colorado Permanente Medical Group, Medical Center of Aurora, Aurora, CO.
Oncology (Williston Park). 2020 Sep 15;34(9):367-369. doi: 10.46883/ONC.2020.3409.0367.
Disease progression or recurrence after a period of remission can be a challenging event for individuals seeking cancer treatment. Those referred for possible phase 1 trial enrollment are often motivated to participate in these studies with hope for a cure despite approximately 5% response rates in this setting. Addressing such commonly held misunderstandings during the initial evaluation for phase 1 trial eligibility could provide a valuable opportunity to improve physician communication by identifying signs of distress or psychiatric conditions, addressing underlying psychological biases, and encouraging adaptive coping strategies.
对于寻求癌症治疗的个体而言，病情缓解一段时间后疾病进展或复发可能是一个具有挑战性的情况。那些被转诊以考虑纳入1期试验的患者，尽管在此种情况下缓解率约为5%，但他们通常仍有动力参与这些研究，希望能够治愈疾病。在对1期试验资格进行初步评估时，解决这些普遍存在的误解，可能会提供一个宝贵的机会，通过识别痛苦迹象或精神疾病状况、解决潜在的心理偏见以及鼓励适应性应对策略，来改善医生与患者之间的沟通。
